⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 13, 2024

Table S1 from Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations

Ursula Grazini Aleksandra Markovets Lucy Ireland Daniel O’Neill Benjamin Phillips Man Xu Matthias Pfeifer Tereza Vaclová Matthew J. Martin Ludovic Bigot Luc Friboulet Ryan J. Hartmaier Maria Emanuela Cuomo Simon T. Barry Paul D. Smith Nicolas Floc’h

View at Publisher

Ask AI

Bookmark

Share

Abstract

Table S1: Statistical comparison between treatment arms for the on-treatment phase in PC9 PIK3CAm xenograft models described in Figure 5E.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Grazini et al. (2024) studied this question.

synapsesocial.com/papers/68e58a5ab6db6435875263e1 https://doi.org/10.1158/1078-0432.27013628

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Table S1 from Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations2024
2Figure S4 from Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations2024
3Figure S3 from Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations2024
4Figure S5 from Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations2024
5Figure S2 from Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations2024

Figure S1 from Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations2024
Data from Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations2024
Supplementary Figure S8 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC2024